CN101461785B - Oil in water-oil in oil-water in oil method for preparing microballoons - Google Patents
Oil in water-oil in oil-water in oil method for preparing microballoons Download PDFInfo
- Publication number
- CN101461785B CN101461785B CN200910045024A CN200910045024A CN101461785B CN 101461785 B CN101461785 B CN 101461785B CN 200910045024 A CN200910045024 A CN 200910045024A CN 200910045024 A CN200910045024 A CN 200910045024A CN 101461785 B CN101461785 B CN 101461785B
- Authority
- CN
- China
- Prior art keywords
- peg
- plga
- pla
- microsphere
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a method for preparing microspheres by water-in-oil-in-oil-in-water in the technical field of pharmacy, which comprises the following steps: a medicine solution is prepared first, and is dispersed into an organic solution with a slow release or controlled release functional material, and the stirring or swirling and so on is preformed to make the medicine solution dispersed evenly to form a suspension; then the suspension is added into an external oil phase to be stirred or swirled to form microspheres, and finally the microspheres are transferred into a large water phase for solidification; and then the microspheres are centrifugally collected, freeze-dried and preserved, wherein in the obtained microspheres, the medicine accounts for 0.01 to 50 percent of the weight of the entire microshperes, the slow release or controlled release material accounts for 20 to 99.99 percent of the weight of the entire microshperes, and an auxiliary material accounts for 0 to 30 percent of the weight of the entire microshperes. The microspheres prepared by the method have smooth and round surfaces and good uniformity, are regular, have no adhesion, and have adjustable grain diameters; the used organic solvent is environment-friendly, is easy to remove by water, and does not affect the treatment effect of the medicine; and the microspheres have high envelope rate, and small burst release and incomplete release.
Description
Technical field
What the present invention relates to is the medicine microspheres method for preparing in a kind of pharmaceutical technology field, and especially a kind of oil-in-water-oil bag oil-Water-In-Oil (W/O/O/W) prepares the method for microsphere.
Background technology
Pharmaceutical industry is from drug discovery, and to Clinical Application, last link is pharmaceutical preparation.Wherein some medicine needs long term administration to cure; Some needs topicals such as targeting.Reach these purposes, crude drug must be prepared into corresponding dosage forms.For example need long term administration but short medicine of in vivo half-life should be prepared into slow release formulation; For some tumor treatment, need some drug targetings in the disease photograph, for example targeting is in tumor vascular embolism microball preparation etc.; Gene recombination technology be used to treat proteic expression and production 20 for many years; Up to the present; Existing more than 30 protein drug product drops into clinical use; Nearly 200 examine with R&D process in, emerge and a collection ofly enter (Amgen), gene technology a collection of new large-scale medical companies such as (Genentech) such as peace.With respect to the fast development of protein macromolecule medicine itself, its dosage form technical progress is slow.On the one hand, the protein macromolecule drug oral does not absorb, the interior half-life of body is short, needs drug administration by injection; On the other hand, the protein drug treatment cycle of many He Ermeng, cytokine class is long, and injection for a long time and continually becomes necessary, also influences the main cause of patient's compliance.The research and development of the dosage form of slow release protein drug are owing to cause the not high S/O/W method of active loss such as W/O/W method, envelop rate and be prone to the prominent S/O/O method of releasing etc. in preparation microgranule process.It is imperative with the prominent method of releasing that the protein microsphere that development preparation has an active protection can improve envelop rate again.Also do not see up till now and utilize oil-in-water-oil bag oil-oil bag solid (W/O/O/W) method to prepare the report of microsphere.
Retrieval through to the prior art document is found; O ' Donnell; P.B. wait Biopharmaceutics at European Journal ofPharmaceutics and, 1998,45:83-94; Publishing an article, " Influece ofprocessing on the stability and release prosperities of biodegradablemicrospheres containing thioridazine hydrochloride " (the preparation process is to the stability of the mellaril of mellaril biodegradable microsphere and the influence of release; Europe biological agent and journal of Practical Pharmacy, 1998,45:83-94).O ' Donnell; P.B. wait the people to report that in the document W/O/W and W/O/O multi-emulsion method prepare microsphere; Simultaneously at document the such printed words of W/O/O/O appear also; But read over find that this is that editor misplays or clerical mistake causes W/O/O/O appears in this article because the document has only been reported this common W/O/W and W/O/O multi-emulsion method.The document has been reported the W/O/W method: medicine is dissolved in and forms water (W) in the 0.5ml distilled water.0.8g PLGA is dissolved in the dichloromethane of 8ml and forms oil phase (O).These two solution are mixed and use dispersing emulsification machine emulsifying, make it to form colostrum, add colostrum in the aqueous solution that 80ml contains 2% polyvinyl alcohol (W) to then, and stir 3 hours solidified microspheres.The W/O/O multi-emulsion method: the aqueous solution of medicine is dispersed in the colostrum that forms W/O in the acetonitrile solution of PLGA, then the colostrum that forms again at 0.5% sorbester p17 and stir solidified microsphere, in the document the 3rd oil phase do not appear at all.But all there be easy prominent the releasing of the medicine that is wrapped up in these two kinds of methods, and envelop rate is not high, and has not exclusively release, and also there are the shortcomings such as pollution to environment in the W/O/O method that the document is reported.
Summary of the invention
The objective of the invention is to overcome deficiency of the prior art, provide a kind of oil-in-water-oil bag oil-Water-In-Oil to prepare the method for microsphere.Make the smooth rounding of microparticle surfaces of its preparation, good evenness, granule regular without adhesion; Envelop rate is high, prominently releases for a short time, and drug loading is high, and can overcome the method for above-mentioned shortcoming, and environmentally safe.
The present invention realizes that through following technical scheme the present invention prepares drug solution earlier, drug solution is dispersed in the organic solution with slow release or control-release function material, and the formation suspensions that make it to be uniformly dispersed such as stirring or whirlpool; Then suspension is added to outer oil phase, restir or whirlpool form microsphere, transfer to big aqueous phase to it at last and solidify; Centrifugal then collection microsphere, lyophilizing is preserved.
The present invention includes following steps:
1. prepare drug solution, directly be dissolved in the water medicine or medicine be dissolved in the water through adding adjuvant;
2. the organic solution that drug solution is joined slow release or controlled-release material is oil phase-1 (O
1) in stir or whirlpool etc. makes it homodisperse and forms uniform suspension;
3. suspension being added in another organic solution is oil phase-2 (O
2), this oil phase is not allowed slow release or sky to release material but can be extracted organic solvent 2., and stirring, whirlpool or ultrasonic formation contain the emulsion of 20-500 μ m microsphere;
4. the completing steps emulsion that contains microsphere 3. being transferred to salt water (W) solidifies;
5. completing steps sample lyophilizing is 4. got microsphere, in this microsphere: medicine is that percentage by weight (w/w) 0.01-50%, slow release or the controlled-release material of whole microsphere is that 20-99.99% (w/w), adjuvant are 0-30% (w/w).
Described drug solution refers to medicine dissolution and in water, forms solution, or medicine forms aqueous solution through adding adjuvant;
Described medicine comprises small-molecule drug and macromolecular drug;
Described small-molecule drug is meant chemicals, and macromolecular drug is meant biopharmaceutical macromolecular drug.Further finger protein macromolecular drug, vaccine, antibody, nucleic acid or liposome medicament;
Described protein macromolecule medicine is: erythropoietin (EPO); Recombinant human granulocyte colony stimulating factor (G-CSF); Granulocyte-macrophage colony stimutaing factor (GM-CSF); Vaccine; Interferon (IFN); Growth hormone (GH); Insulin (Insulin); Epidermal growth factor (EGF); Fibroblast growth factor (FGF); Transforming growth factor (TGF-β); Insulin like growth factor (IGF); Vascular endothelial cell growth factor (VEGF); PDGF (PDGF); ECGF (ECGF); Nerve growth factor (NGF); BDGF (BDGF); BMP (BMP); Tissue polypeptide antigen (TPA); Antibody (antibody); Blood coagulation factor VIII (VIII); Or plasma thromboplastin component genetic factor.
Described nucleic acid is: GEM 132 (anti-RNA), microRNA (RNAi) or gene (DNA).
Described adjuvant is meant the little saccharide of injection (sucrose, trehalose, glucose, maltose or lactose), polyhydroxy compounds (mannitol, sorbitol, glycerol, 1,2-propylene glycol, erythritol, Polyethylene Glycol, polyvinyl alcohol, PEO or polypyrrole alkane ketone; ), a kind of or combination in any of polysaccharide compound (glucosan, sodium alginate, chitosan, starch, cellulose or cyclodextrin material), amino-acid compound (propylhomoserin, lysine, arginine, glutamic acid or histidine) and inorganic salts material (zinc salt, calcium salt, mantoquita, magnesium salt or molybdenum salt).
In the described drug solution, the percentage by weight of medicine (w/w) content is between the 0.2-50%; With 1-20% (w/w) is good.
The material of described slow release or controlled release is: polylactic acid; Polylactic acid-polyglycolic acid; Silicon is as glue; Politef; Polrvinyl chloride; Polyethylene; Polypropylene; Polystyrene; PETG; Polybutylcyanoacrylate; Poly phosphazene; Poly phosphate; Fibrinogen; Fibrin; Polyethylene glycol-lactic acid; The polyethylene glycol-hydroxyacetic acid; Polyglycolic acid-polyethylene glycol-hydroxyacetic acid; Polylactic acid-polyglycol-polylactic acid; With polylactic acid; Merlon; Carmomer; Hyaluronic acid; Gelatin; A kind of in collagen protein and the caprolactone.
Described oil phase-1 (O
1) be: the organic solution of the material of slow release or controlled release;
The organic solution of the material of described slow release or controlled release, wherein organic solution is meant a kind of or combination in dichloromethane, ethyl acetate, acetonitrile, heptane, chloroform or the acetone, and is a kind of or be combined as good with dichloromethane, ethyl acetate and acetonitrile.
In the organic solution of the material of described slow release or controlled release, the percentage by weight of the material of slow release or controlled release (w/w) content is 0.5-80%, is good with 5-30% (w/w) wherein.
Described oil phase-2 (O
2) be: a kind of or their combination in any in surfactant, glycerol, ethanol, propylene glycol, ethylene glycol solution and the liquid macrogol;
Described their combination in any is: glycerol and ethanol add that aqueous solution that the aqueous solution of surfactant, aqueous solution, glycerol and propylene glycol that ethanol adds surfactant add surfactant, aqueous solution, glycerol and ethylene glycol that propylene glycol adds surfactant add the aqueous solution of surfactant, aqueous solution, glycerol and the liquid macrogol that ethylene glycol adds surfactant adds the aqueous solution of surfactant and the combination in any that liquid macrogol adds surfactant;
Described aqueous surfactant solution is: polyvinyl alcohol (PVA), Polyethylene Glycol (PEG), polyvinylpyrrolidone (PVP), poloxamer (poloxmer), gather in sorbic alcohol, ethyl cellulose (EC) or the tween a kind of; Wherein: the weight concentration percentage by weight (w/w) of polyvinyl alcohol (PVA) is for 0.5-10% or contain saline solution such as 0.5-10% (w/w) sodium chloride; The weight concentration of Polyethylene Glycol (PEG) is 0.5-20% (w/w) or the saline solution that contains 0.5-10% (w/w) sodium chloride; Polyvinylpyrrolidone (PVP) weight concentration is 0.5-20% (w/w) or contains saline solution such as 0.5-10% (w/w) sodium chloride; Poloxamer (poloxmer) weight concentration is 0.5-20% (w/w) or contains saline solution such as 0.5-10% (w/w) sodium chloride; To gather the sorbic alcohol weight concentration be 0.5-20% (w/w) or contain saline solution such as 0.5-10% (w/w) sodium chloride, and ethyl cellulose (EC) weight concentration is 0.5-20% or contains saline solution such as 0.5-10% sodium chloride.
Said oil phase-2 (O
2) ratio be: glycerol percentage by weight (w/w) 0-50%, aqueous surfactant solution 0-30% (w/w), ethanol, propylene glycol, ethylene glycol or liquid macrogol 50-100% (w/w).
The particle diameter of said microsphere is 1-300 μ m, is good with 20-100 μ m.
The present invention has selected suitable oils-1 (O
1) and oil phase-2 (O
2) and the material of suitable controlled release and slow release; Make water miscible drug solution or oil-soluble medicine be prepared into oily insoluble granule through the method for preparation; Avoid the not high and S/O/O of envelop rate with conventional W/O, W/O/W, S/O/W prominent release serious, and the shortcoming of the environmental pollution that causes; Adopt this method to prepare microsphere, the size of its particle diameter can be controlled according to different needs, and is free from environmental pollution; Can avoid the function influence to the treatment of medicine, especially those physicochemical properties are unsettled, and the medicine responsive to oil-water interfaces is like biopharmaceutical macromolecular drug protein macromolecule medicine.The smooth surface rounding of microgranule, the granule regular without adhesion, particle diameter can be regulated and control from 1 μ m to 500 μ m as required, and its freeze dried powder is that white is fine and smooth, and is loose, can not subside, adhesion, redispersibility is good.Can apply to the preparation of various medicament slow-release microspheres and the adjuvant of vaccine.
The specific embodiment
Elaborate in the face of embodiments of the invention down: present embodiment provided detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following embodiment being to implement under the prerequisite with technical scheme of the present invention.
Embodiment one: be loaded with the preparation of small-molecule drug PLGA microsphere
(1) preparation drug solution directly or through adding adjuvant is dissolved in the water small-molecule drug;
In the present embodiment, the small-molecule drug of employing is that (tumor chemotherapeutic drug is selected from chemotherapy of tumors class medicine: AC, dactinomycin, bleomycin, daunorubicin, amycin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), semustine, cisplatin, etoposide, camptothecine and derivant, phenesterin, paclitaxel and derivant thereof, Docetaxel and derivant thereof, vinblastine, vincristine, zitazonium, etoposide, piposulfan, cyclophosphamide or flutamide and derivant thereof; Sustained-release micro-spheres can be loaded with one or more in the said medicine; ) or antibiotics (antibiotics is selected from ciclosporin, levofloxacin, ofloxacin or epinastine hydrochloride; Sustained-release micro-spheres can be loaded with one or more in the said medicine).
In the present embodiment, the adjuvant of employing is one or more in glucosan, sodium alginate, chitosan, starch, cellulose, cyclodextrin, Polyethylene Glycol, polyvinyl alcohol, PEO, polypyrrole alkane ketone, sucrose, trehalose, mannitol, sorbitol, lactose, glycine, lysine, zinc salt, calcium salt, mantoquita, magnesium salt, molybdenum salt or the histidine said medicine;
In the present embodiment, the weight ratio of adjuvant and small-molecule drug is 0%-99.99% (w/w); Concrete proportioning situation such as following table:
Medicine | Adjuvant | Medicine accounts for the percentage by weight of solution gross weight | Medicine | Adjuvant | Medicine accounts for the percentage by weight of solution gross weight |
Amycin 1 | Cyclodextrin | 100%, 80%, 50 %, 25% or 0% | Carboplatin 1 | Cyclodextrin | 100%, 80%, 50 %, 25% or 0% |
Amycin 2 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% | Carmustine | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% |
Amycin 3 | Polyvinyl alcohol | 100%, 80%, 50 %, 25% or 0% | Semustine | Polyvinyl alcohol | 100%, 80%, 50 %, 25% or 0% |
Amycin 4 | PEO | 100%, 80%, 50 %, 25% or 0% | Cisplatin | PEO | 100%, 80%, 50 %, 25% or 0% |
Amycin 5 | Polypyrrole alkane ketone | 100%, 80%, 50 %, 25% or 0% | Etoposide | Polypyrrole alkane ketone | 100%, 80%, 50 %, 25% or 0% |
Cyclophosphamide 1 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% | Camptothecine | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% |
Dactinomycin 1 | PEO | 100%, 80%, 50 %, 25% or 0% | Phenesterin | PEO | 100%, 80%, 50 %, 25% or 0% |
Daunorubicin 1 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% | Paclitaxel | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 10% |
Amycin 6 | PEO | 100%, 80%, 50 %, 25% or 0% | Docetaxel | PEO | 100%, 80%, 50 %, 25% or 0% |
Epirubicin 1 | Polypyrrole alkane ketone | 100%, 80%, 50 %, 25% or 0% | Vinblastine | Polypyrrole alkane ketone | 100%, 80%, 50 %, 25% or 0% |
Methotrexate 1 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% | Vincristine | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% |
Fluorouracil 1 | PEO | 100%, 80%, 50 %, 25% or 0% | Zitazonium | PEO | 100%, 80%, 50 %, 25% or 0% |
Etoposide 1 | Cyclodextrin | 100%, 80%, 50 %, 25% or 0% | Piposulfan | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% |
Flutamide 1 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 0% | Daunorubicin and carboplatin | PEO | 100%, 80%, 50 %, 25% or 0% |
Amycin and paclitaxel | Polyvinyl alcohol | 100%, 80%, 50 %, 25% or 0% | Ciclosporin 2 | Polypyrrole alkane ketone | 100%, 80%, 50 %, 25% or 0% |
Ciclosporin 1 | PEO | 100%, 80%, 50 %, 25% or 0% | Levofloxacin 3 | PEO | 100%, 90%, 80 %, 40% or 20% |
Levofloxacin 1 | Polypyrrole alkane ketone | 100%, 80%, 40 %, 20% or 0% | Ofloxacin 3 | Polyethylene Glycol | 100%, 80%, 40 %, 20% or 0% |
Ofloxacin 1 | Glucosan | 100%, 80%, 40 %, 10% or 0% | Epinastine hydrochloride 3 | PEO | 100%、80%、40 %、20%、0.1% |
Hydrochloric acid according to | Sodium alginate | ?100%、80%、40 | Levofloxacin | Mannitol | 100%、80%、40 |
This spit of fland 1 | %, 20% or 0% | Star 3 | %, 20% or 0% | ||
Levofloxacin 2 | Chitosan | 100%, 80%, 40 %, 20% or 0% | Ofloxacin 4 | Sorbitol | 100%, 80%, 40 %, 20% or 0% |
Ofloxacin 2 | Starch | 100%、80%、40 %、20%、0.1% | Epinastine hydrochloride 3 | Lactose | 100%, 80%, 40 %, 20% or 0% |
Epinastine hydrochloride 1 | Cellulose | 100%, 80%, 40 %, 20% or 0% | Levofloxacin 4 | Glycine | 100%, 80%, 40 %, 20% or 0% |
Ofloxacin 3 | Sucrose | 100%, 80%, 40 %, 20% or 0% | Ofloxacin 5 | Lysine | 100%, 80%, 40 %, 20% or 0% |
Epinastine hydrochloride 2 | Trehalose | 100%, 80%, 40 %, 20% or 0% | Epinastine hydrochloride 4 | Histidine | 100%, 80%, 40 %, 20% or 0% |
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLGA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
(3) getting emulsion droplets to step (2) is added to oil phase-2 and stirring, whirlpool or formed emulsion in ultrasonic 0.5-5 minute;
(4) be added drop-wise to the emulsion of step (3) in the 1000ml sodium chloride solution that concentration is 1-10% (w/w) and stir and solidified 1-4 hour;
(5) the centrifugal collection microsphere that obtains step (4), and, obtain microsphere after the lyophilizing with water washing 3-5 time.
The microsphere that present embodiment obtains, its concrete set of dispense ratio sees the following form:
Drug solution | PLGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA | Drug solution accounts for the percentage by weight of gross weight |
Amycin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLGA | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLGA | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLGA | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLGA | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PLGA | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PLGA | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLGA | 20%、60%、80%、 | Phenesterin | PLGA | 20%、60%、40%、 |
70% or 99.99% | 70% or 99.99% | ||||
Daunorubicin 1 | PLGA | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PLGA | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PLGA | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLGA | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment two: be loaded with the preparation of biopharmaceutical macromolecular drug PLGA microsphere
(1) preparation biopharmaceutical macromolecular drug solution is dissolved in the water biopharmaceutical macromolecular drug through adding adjuvant;
In the present embodiment, the biopharmaceutical macromolecular drug of employing is erythropoietin (EPO), recombinant human granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimutaing factor (GM-CSF), vaccine, interferon (INF), growth hormone (GH), insulin (Insulin), epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF-β), insulin like growth factor (IGF), vascular endothelial cell growth factor (VEGF), PDGF (PDGF), ECGF (ECGF), nerve growth factor (NGF), BDGF (BDGF), BMP (BMP), tissue polypeptide antigen (TPA), antibody (antibody), blood coagulation factor VIII (VIII), IX genetic factor, GEM 132 (anti-RNA), microRNA (RNAi), SiRNA, gene (DNA); Sustained-release micro-spheres can be loaded with one or more in the said medicine.
In the present embodiment, the adjuvant of employing is one or more in glucosan, sodium alginate, chitosan, starch, cellulose, cyclodextrin, Polyethylene Glycol, polyvinyl alcohol, PEO, polypyrrole alkane ketone, sucrose, trehalose, mannitol, sorbitol, lactose, glycine, lysine or the histidine said medicine;
In the present embodiment, the proportioning of concrete material sees the following form:
Medicine | Adjuvant | Medicine accounts for the percentage by weight of solution | Medicine | Adjuvant | Medicine accounts for the percentage by weight of solution |
EPO1 | Glucosan | 80%, 50%, 25 %, 10% or 5% | ?NGF | Cyclodextrin and sucrose (5: 1) | 100%, 80%, 50 %, 25% or 10 % |
G-CSF1 | Glucosan and trehalose (9: 1) | 80%, 50%, 25 %, 10% or 5% | ?BDGF3 | Polyethylene Glycol and sorbitol (8: 1) | 100%, 80%, 50 %, 25% or 10 % |
GM-CSF1 | Glucosan and trehalose (9: 1) | 80%, 50%, 25 %, 10% or 5% | ?BMP2 | Glucosan | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
Vaccine 1 | Glucosan | 100%, 80%, 50 %, 25% or 10% | ?TPA2 | PEO and sucrose (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
GH1 | Glucosan zinc salt and mannitol (9: | 80%, 50%, 25% or 10% | ?antibody | Polypyrrole alkane ketone and sweet ammonia | ?50%、40%、30?%、25%、15 |
0.5∶1) | Acid (5: 1) | %, 10% or 5% | |||
Insulin | Polyethylene Glycol and zinc salt (9: 1) | 100%, 80%, 50 %, 25% or 10% | Blood coagulation factor VIII | Glucosan and lysine (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
EGF1 | PEO | 100%, 80%, 50 %, 25% or 10% | The IX genetic factor | Glucosan and histidine (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
FGF1 | Polyethylene Glycol | 100%, 80%, 50 %, 25% or 10% | anti-RNA | Polyethylene Glycol | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
TGF-β | PEO | 100%, 80%, 50 %, 25% or 10% | RNAi | PEO | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
IGF | Glucosan | 100%, 80%, 50 %, 25% or 10 % | SiRNA | Glucosan | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
VEGF | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15%, 10% or 5% | DNA | Glucosan | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
PDGF1 | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15%, 10% or 5% | BDGF and BMP (1: 1) | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
ECGF | Cyclodextrin and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15%, 10% or 5% | PDGF and BMP (1: 1) | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
VEGF and DNA (1: 1) | Glucosan and trehalose (8: 1) | 80%, 70%, 50 %, 25% or 10 % | TGF-β, PDGF and BMP (1: 1: 1) | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
NGF and BM P (1: 1) | Glucosan and lactose (8: 1) | 80%, 60%, 50 %, 25% or 10 % | SiRNA and DNA (1: 1) | Polypyrrole alkane ketone | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
EGF and FG F (1: 1) | Glucosan and trehalose (8: 1) | 60%, 50%, 25 %, 10% or 5% | BDGF and VEGF (1: 1) | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
GM-CSF and G-CSF (1: 1) | Glucosan and lactose (8: 1) | 60%, 50%, 25 %, 10% or 5% | IGF and GH (1: 1) | Glucosan and trehalose (8: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
VEGF and DNA (1: 1) | Glucosan and sodium alginate (9: 1) | 60%, 50%, 25 %, 10% or 5% | EPO2 | Glucosan and sodium alginate (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
NGF and BM P (1: 1) | Glucosan and sodium alginate (9: 1) | 60%, 50%, 40 %, 20%, 10% or 5% | G-CSF2 | Glucosan and sodium alginate (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
EGF and FG F (1: 1) | Chitosan | 60%, 50%, 40 %, 20%, 10% or 5% | GM-CSF2 | Glucosan and sorbitol (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
GM-CSF and G-CSF (1: 1) | Starch | 60%, 50%, 40 %, 20%, 10% or 5%% | Vaccine | Glucosan and lactose (9: 1) | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
BDGF2 | Cellulose and lactose (9: 1) | ?100%、80%、40?%、20%、10% | EPO3 | Glucosan and glycine | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
BMP1 | Glucosan and sucrose (9: 1) | ?100%、80%、40?%、20%、10% | G-CSF3 | Glucosan and lysine | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
TPA1 | Trehalose | ?100%、80%、40?%、20%、10% | GM-CSF3 | Glucosan and histidine | 50%, 40%, 30 %, 25%, 15 %, 10% or 5% |
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PLGA of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, it specifically forms proportioning such as following table:
Drug solution | PLGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | NGF | PLGA | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PLGA | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLGA | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PLGA | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLGA | 20%、60%、80%、 | antibody | PLGA | 20%、50%、80%、 |
50% or 99.99% | 70% or 99.99% | ||||
Insulin | PLGA | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PLGA | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PLGA | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLGA | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PLGA | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLGA | 20%, 60%, 80%, 70% or 99.99% | RNAi | PLGA | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PLGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLGA | 20%, 60%, 80%, 70% or 99.99% | DNA | PLGA | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PLGA | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PLGA | 20%, 40%, 80%, 70% or 99.99% |
EGF and FGF (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PLGA | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PLGA | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | EPO2 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PLGA | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PLGA | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLGA | 20%, 60%, 78%, 70% or 99.99% | EPO3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PLGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment three: be loaded with the preparation of small-molecule drug PLA microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLA | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLA | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLA | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLA | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLA | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLA | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PLA | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PLA | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLA | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PLA | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PLA | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLA | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLA | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLA | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLA | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLA | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLA | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PLA | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PLA | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLA | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment four: be loaded with the preparation of biopharmaceutical macromolecular drug solution PLA microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PLA of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLA | 20%, 60%, 80%, 70% or 99.99% | NGF | PLA | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLA | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLA | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PLA | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLA | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PLA | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLA | 20%, 60%, 80%, 50% or 99.99% | antibody | PLA | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PLA | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PLA | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLA | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PLA | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLA | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PLA | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLA | 20%, 60%, 80%, 70% or 99.99% | RNAi | PLA | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLA | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PLA | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLA | 20%, 60%, 80%, 70% or 99.99% | DNA | PLA | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLA | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PLA | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP | PLA | 20%、60%、80%、 | SiRNA and DNA | PLA | 20%、40%、80%、 |
(1∶1) | 70% or 99.99% | ?(1∶1) | 70% or 99.99% | ||
EGF and FGF (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PLA | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PLA | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | ?EPO2 | PLA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | ?G-CSF2 | PLA | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | ?GM-CSF2 | PLA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PLA | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLA | 20%, 60%, 78%, 70% or 99.99% | ?EPO3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLA | 20%, 60%, 80%, 70% or 99.99% | ?G-CSF3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLA | 20%, 60%, 80%, 70% or 99.99% | ?GM-CSF3 | PLA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment five: be loaded with the preparation of small-molecule drug solution PGA microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PGA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PGA | Drug solution accounts for the percentage by weight of microsphere gross weight |
Amycin 1 | PGA | 20%、60%、80%、 | Carboplatin 1 | PGA | 20%、60%、80%、 |
70% or 99.99% | 70% or 99.99% | ||||
Amycin 2 | PGA | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PGA | 20%, 60%, 80%, 70% or 99.99% | Semustine | PGA | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PGA | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PGA | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PGA | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PGA | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PGA | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PGA | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PGA | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PGA | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PGA | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PGA | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PGA | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PGA | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PGA | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PGA | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PGA | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PGA | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PGA | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PGA | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PGA | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PGA | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment six: be loaded with the preparation of biopharmaceutical macromolecular drug solution PGA microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PGA of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PGA | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PGA | 20%, 60%, 80%, 70% or 99.99% | NGF | PGA | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PGA | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PGA | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PGA | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PGA | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PGA | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PGA | 20%, 60%, 80%, 50% or 99.99% | antibody | PGA | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PGA | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PGA | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PGA | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PGA | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PGA | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PGA | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PGA | 20%, 60%, 80%, 70% or 99.99% | RNAi | PGA | 20%, 60%, 80%, 70% or 99.99% |
IGF | PGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PGA | 20%, 60%, 80%, 70% or 99.99% | DNA | PGA | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PGA | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PGA | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PGA | 20%, 40%, 80%, 70% or 99.99% |
EGF and FGF (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PGA | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PGA | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | EPO2 | PGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PGA | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PGA | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PGA | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PGA | 20%, 60%, 78%, 70% or 99.99% | EPO3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment seven: be loaded with the preparation of small-molecule drug polycaprolactone microballoon sphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and polycaprolactone is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | Polycaprolactone | Drug solution accounts for the percentage by weight of microsphere | Drug solution | Polycaprolactone | Drug solution accounts for the percentage by weight of microsphere gross weight |
Amycin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Carmustine | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Semustine | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% | Etoposide | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | Polycaprolactone | 20%、60%、80%、 | Vincristine | Polycaprolactone | 20%、60%、80%、 |
70% or 99.99% | 70% or 99.99% | ||||
Fluorouracil 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Polycaprolactone | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment eight: be loaded with the preparation of biopharmaceutical macromolecular drug solution polycaprolactone microballoon sphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and polycaprolactone of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | Polycaprolactone | Drug solution accounts for the percentage by weight of microsphere | Drug solution | Polycaprolactone | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | NGF | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | BMP2 | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% | TPA2 | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% |
GH1 | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% | antibody | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% |
Insulin | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | RNAi | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
IGF | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | SiRNA | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
VEGF | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | DNA | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
ECGF | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | Polycaprolactone | 20%, 40%, 80%, 70% or 99.99% |
1) | |||||
EGF and FGF (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | Polycaprolactone | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | Polycaprolactone | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | EPO2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | Polycaprolactone | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | Vaccine | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | Polycaprolactone | 20%, 60%, 78%, 70% or 99.99% | EPO3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | Polycaprolactone | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment nine: be loaded with the preparation of small-molecule drug solution PLA-PEG microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLA-PEG is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA-PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA-PEG | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA-PEG | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment ten: be loaded with the preparation of biopharmaceutical macromolecular drug solution PLA-PEG microsphere
Step (1) is identical with embodiment one.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PLA-PEG of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA-PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA-PEG | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | NGF | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% | antibody | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | RNAi | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | DNA | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PLA-PEG | 20%, 40%, 80%, 70% or 99.99% |
EGF and FG F (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PLA-PEG | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PLA-PEG | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | EPO2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PLA-PEG | 20%, 60%, 40%, 70% or 99.99% |
EGF and FG F (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLA-PEG | 20%, 60%, 78%, 70% or 99.99% | EPO3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PLA-PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 11: be loaded with the preparation of small-molecule drug solution PLGA-PEG microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLGA-PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA-PEG | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLGA-PEG | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLGA-PEG | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLGA-PEG | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLGA-PEG | 20%、60%、80%、 | Etoposide | PLGA-PEG | 20%、50%、80%、 |
50% or 99.99% | 70% or 99.99% | ||||
Cyclophosphamide 1 | PLGA-PEG | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PLGA-PEG | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PLGA-PEG | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PLGA-PEG | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA-PEG | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLGA-PEG | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA-PEG | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA-PEG | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLGA-PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 12: be loaded with the preparation of biopharmaceutical macromolecular drug solution PLGA-PEG microsphere
Step (1) is identical with embodiment one.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PLGA-PEG of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLGA- PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA- PEG | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | NGF | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PLGA- PEG | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLGA- PEG | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PLGA- PEG | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLGA- PEG | 20%, 60%, 80%, 50% or 99.99% | antibody | PLGA- PEG | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PLGA- PEG | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PLGA- PEG | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLGA- PEG | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | RNAi | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | DNA | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PLGA- PEG | 20%, 40%, 80%, 70% or 99.99% |
EGF and FG F (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PLGA- PEG | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PLGA- PEG | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | EPO2 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PLGA- PEG | 20%, 60%, 40%, 70% or 99.99% |
EGF and FG F (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLGA- PEG | 20%, 60%, 78%, 70% or 99.99% | EPO3 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 13: be loaded with the preparation of small-molecule drug solution PLA-PEG-PLA microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLA-PEG-PLA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA-PEG -PLA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA-PEG -PLA | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLA-PEG -PLA | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLA-PEG -PLA | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLA-PEG -PLA | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLA-PEG -PLA | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PLA-PEG -PLA | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PLA-PEG -PLA | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PLA-PEG -PLA | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PLA-PEG -PLA | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Amycin | PLA-PEG | 20%、60%、80%、 | Ciclosporin 2 | PLA-PEG | 20%、40%、80%、 |
And paclitaxel | -PLA | 70% or 99.99% | -PLA | 70% or 99.99% | |
Ciclosporin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA-PEG -PLA | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLA-PEG -PLA | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLA-PEG -PLA | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLA-PEG -PLA | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 14: be loaded with the preparation of biopharmaceutical macromolecular drug solution PLA-PEG-PLA microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PEG-PLA-PEG of complex is to form even suspension Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLA-PEG -PLA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLA-PEG -PLA | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | NGF | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | BDGF3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | BMP2 | PLA-PEG -PLA | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLA-PEG -PLA | 20%, 40%, 80 %, 70% or 99.99% | TPA2 | PLA-PEG -PLA | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLA-PEG -PLA | 20%, 60%, 80 %, 50% or 99.99% | antibody | PLA-PEG -PLA | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PLA-PEG -PLA | 20%, 50%, 80 %, 70% or 99.99% | Blood coagulation factor VIII | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | The IX genetic factor | PLA-PEG -PLA | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLA-PEG -PLA | 20%, 60%, 40 %, 70% or 99.99% | anti-RNA | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | RNAi | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | SiRNA | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | DNA | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | BDGF and BMP (1: 1) | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | PDGF and BMP (1: 1) | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
VEGF with | PLA-PEG | 20%、60%、80 | TGF-β、 | PLA-PEG | 20%、60%、80%、 |
DNA(1∶1) | -PLA | %, 70% or 99.99% | PDGF and BMP (1: 1: 1) | -PLA | 70% or 99.99% |
NGF and BMP (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | SiRNA and DNA (1: 1) | PLA-PEG -PLA | 20%, 40%, 80%, 70% or 99.99% |
EGF and FGF (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | BDGF and VEGF (1: 1) | PLA-PEG -PLA | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | IGF and GH (1: 1) | PLA-PEG -PLA | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | EPO2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | G-CSF2 | PLA-PEG -PLA | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | GM-CSF2 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | Vaccine | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLA-PEG -PLA | 20%, 60%, 78 %, 70% or 99.99% | EPO3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | G-CSF3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLA-PEG -PLA | 20%, 60%, 80 %, 70% or 99.99% | GM-CSF3 | PLA-PEG -PLA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 15: be loaded with the preparation of small-molecule drug solution PLGA-PEG-PLGA microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PLGA-PEG-PLGA is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLGA-PEG -PLGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA-PEG -PLGA | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Semustine | PLGA-PEG -PLGA | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PLGA-PEG -PLGA | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PLGA-PEG -PLGA | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PLGA-PEG -PLGA | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PLGA-PEG -PLGA | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PLGA-PEG -PLGA | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PLGA-PEG -PLGA | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PLGA-PEG -PLGA | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Vincristine | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PLGA-PEG | 20%、60%、80%、 | Daunorubicin | PLGA-PEG | 20%、60%、80%、 |
-PLGA | 70% or 99.99% | And carboplatin | -PLGA | 70% or 99.99% | |
Amycin and paclitaxel | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PLGA-PEG -PLGA | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PLGA-PEG -PLGA | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PLGA-PEG -PLGA | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PLGA-PEG -PLGA | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 16: be loaded with the preparation of biopharmaceutical macromolecular drug solution PLGA-PEG-PLGA microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PLGA-PEG-PLGA of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PLGA?- PEG - PLGA | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PLGA-PEG -PLGA | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | NGF | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PLGA-PEG -PLGA | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PLGA?- PEG - PLGA | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 50% or 99.99% | antibody | PLGA-PEG -PLGA | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PLGA?- PEG - PLGA | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PLGA-PEG -PLGA | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PLGA?- PEG - PLGA | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | RNAi | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
IGF | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | DNA | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | PLGA?- PEG - | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
PLGA | |||||
ECGF | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PLGA-PEG -PLGA | 20%, 40%, 80%, 70% or 99.99% |
EGF and FG F (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PLGA-PEG -PLGA | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PLGA-PEG -PLGA | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | EPO2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PLGA-PEG -PLGA | 20%, 60%, 40%, 70% or 99.99% |
EGF and FG F (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PLGA?- PEG - PLGA | 20%, 60%, 78%, 70% or 99.99% | EPO3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PLGA?- PEG - PLGA | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PLGA-PEG -PLGA | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 17: be loaded with the preparation of small-molecule drug solution PEG-PLA-PEG microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PEG-PLA-PEG is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PEG-PLA -PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PEG-PLA -PEG | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Carmustine | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Semustine | PEG-PLA -PEG | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PEG-PLA -PEG | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | PEG-PLA -PEG | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PEG-PLA -PEG | 20%, 60%, 80%, 50% or 99.99% | Etoposide | PEG-PLA -PEG | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PEG-PLA -PEG | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | PEG-PLA -PEG | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PEG-PLA -PEG | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
First ammonia butterfly | PEG-PLA | 20%、60%、80%、 | Vincristine | PEG-PLA | 20%、60%、80%、 |
Purine 1 | -PEG | 70% or 99.99% | -PEG | 70% or 99.99% | |
Fluorouracil 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | PEG-PLA -PEG | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PEG-PLA -PEG | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | PEG-PLA -PEG | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | PEG-PLA -PEG | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PEG-PLA -PEG | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 18: be loaded with the preparation of biopharmaceutical macromolecular drug solution PEG-PLA-PEG microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PEG-PLA-PEG of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PEG-PLA -PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PEG-PLA- PEG | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | NGF | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
G-CS F1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-C SF1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | BMP2 | PEG-PLA- PEG | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PEG-PLA -PEG | 20%, 40%, 80%, 70% or 99.99% | TPA2 | PEG-PLA- PEG | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PEG-PLA -PEG | 20%, 60%, 80%, 50% or 99.99% | antibod y | PEG-PLA- PEG | 20%, 50%, 80%, 70% or 99.99% |
Insu lin | PEG-PLA -PEG | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | PEG-PLA- PEG | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PEG-PLA -PEG | 20%, 60%, 40%, 70% or 99.99% | anti-RN A | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
TGF- β | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | RNAi | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
IGF | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | DNA | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
PDGF 1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
1) | ) | ||||
NGF and BM P (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | PEG-PLA- PEG | 20%, 40%, 80%, 70% or 99.99% |
EGF and FG F (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | PEG-PLA- PEG | 20%, 60%, 80%, 50% or 99.99% |
GM-C SF and G-CS F (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | PEG-PLA- PEG | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | EP02 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | PEG-PLA- PEG | 20%, 60%, 40%, 70% or 99.99% |
EGF and FG F (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-C SF and G-CS F (1: 1) | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | Vaccine | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
BDGF 2 | PEG-PLA -PEG | 20%, 60%, 78%, 70% or 99.99% | EP03 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | PEG-PLA -PEG | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | PEG-PLA- PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 19: be loaded with the preparation of small-molecule drug solution PEG-PLGA-PEG microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and PEG-PLGA-PEG is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PEG-PLGA -PEG | Drug solution accounts for the percentage by weight of microsphere | Drug solution | PEG-PLGA- PEG | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Carboplatin 1 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Carmustine | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Semustine | PEG-PLGA- PEG | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | PEG-PLGA -PEG | 20%, 40%, 80%, 70 % or 99.99% | Cisplatin | PEG-PLGA- PEG | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | PEG-PLGA -PEG | 20%, 60%, 80%, 50 % or 99.99% | Etoposide | PEG-PLGA- PEG | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | PEG-PLGA -PEG | 20%, 50%, 80%, 70 % or 99.99% | Camptothecine | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Phenesterin | PEG-PLGA- PEG | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | PEG-PLGA -PEG | 20%, 60%, 40%, 70 % or 99.99% | Paclitaxel | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Docetaxel | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Vinblastine | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
First ammonia butterfly | PEG-PLGA | 20%、60%、80%、70 | Vincristine | PEG-PLGA- | 20%、60%、80%、 |
Purine 1 | -PEG | % or 99.99% | PEG | 70% or 99.99% | |
Fluorouracil 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Zitazonium | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Piposulfan | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Daunorubicin and carboplatin | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Ciclosporin 2 | PEG-PLGA- PEG | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Levofloxacin 3 | PEG-PLGA- PEG | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Ofloxacin 3 | PEG-PLGA- PEG | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Epinastine hydrochloride 3 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Levofloxacin 3 | PEG-PLGA- PEG | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Ofloxacin 4 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Epinastine hydrochloride 3 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | PEG-PLGA -PEG | 20%, 60%, 78%, 70 % or 99.99% | Levofloxacin 4 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Ofloxacin 5 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70 % or 99.99% | Epinastine hydrochloride 4 | PEG-PLGA- PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 20: be loaded with the preparation of biopharmaceutical macromolecular drug solution PEG-PLGA-PEG microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and PEG-PLGA-PEG of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | PEG-PLGA -PEG | Drug particles accounts for the percentage by weight of microsphere | Drug solution | PEG-PLGA -PEG | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | NGF | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | BDGF3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | BMP2 | PEG-PLGA -PEG | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | PEG-PLGA -PEG | 20%, 40%, 80 %, 70% or 99.99% | TPA2 | PEG-PLGA -PEG | 20%, 60%, 80%, 50% or 99.99% |
GH1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 50% or 99.99% | antibo dy | PEG-PLGA -PEG | 20%, 50%, 80%, 70% or 99.99% |
Insulin | PEG-PLGA -PEG | 20%, 50%, 80 %, 70% or 99.99% | Blood coagulation factor VIII | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | The IX genetic factor | PEG-PLGA -PEG | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | PEG-PLGA -PEG | 20%, 60%, 40 %, 70% or 99.99% | anti-R NA | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | RNAi | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
IGF | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | SiRNA | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF | PEG-PLGA | 20%、60%、80 | DNA | PEG-PLGA | 20%、60%、80%、 |
-PEG | %, 70% or 99.99% | -PEG | 70% or 99.99% | ||
PDGF1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | BDGF and BMP (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
ECGF | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | PDGF and BMP (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | SiRNA and DNA (1: 1) | PEG-PLGA -PEG | 20%, 40%, 80%, 70% or 99.99% |
EGF and FG F (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | BDGF and VEGF (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | IGF and GH (1: 1) | PEG-PLGA -PEG | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | EPO2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
NGF and BM P (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | G-CSF2 | PEG-PLGA -PEG | 20%, 60%, 40%, 70% or 99.99% |
EGF and FG F (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | GM-CSF 2 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | Vaccine | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | PEG-PLGA -PEG | 20%, 60%, 78 %, 70% or 99.99% | EPO3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or | G-CSF3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
99.99% | |||||
TPA1 | PEG-PLGA -PEG | 20%, 60%, 80 %, 70% or 99.99% | GM-CSF 3 | PEG-PLGA -PEG | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 21: be loaded with the preparation of small-molecule drug solution hyaluronic acid microsphere
Step (1) is identical with embodiment one.
(2) be that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O according to drug solution and hyaluronic dichloromethane, acetonitrile or ethyl acetate solution
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, its concrete set of dispense are such as following table:
Drug solution | Hyaluronic acid | Drug solution accounts for the percentage by weight of microsphere | Drug solution | Hyaluronic acid | Drug solution accounts for the percentage by weight of microsphere |
Amycin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Carmustine | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Semustine | Hyaluronic acid | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | Hyaluronic acid | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | Hyaluronic acid | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | Hyaluronic acid | 20%, 60%, 80%, 50% or 99.99% | Etoposide | Hyaluronic acid | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | Hyaluronic acid | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | Hyaluronic acid | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | Hyaluronic acid | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Vincristine | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | Hyaluronic acid | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Hyaluronic acid | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | Hyaluronic acid | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Hyaluronic acid | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Hyaluronic acid | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | Hyaluronic acid | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 22: be loaded with the preparation of biopharmaceutical macromolecular drug solution hyaluronic acid microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that drug solution and hyaluronic dichloromethane, acetonitrile or the ethyl acetate solution of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The present embodiment thus obtained microsphere, it specifically forms proportioning such as following table:
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Embodiment 23: be loaded with the preparation of small-molecule drug solution gelatine microsphere
Step (1) is identical with embodiment one.
(2) dichloromethane, acetonitrile or the ethyl acetate solution according to drug solution and gelatin is that formation in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute is even that suspension is Water-In-Oil (W/O
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The present embodiment thus obtained microsphere, it specifically forms proportioning such as following table:
Drug solution | Gelatin | Drug solution accounts for microsphere | Drug particles | Gelatin | Drug solution accounts for the weight of microsphere |
Percentage by weight | Percentage ratio | ||||
Amycin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Carboplatin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Amycin 2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Carmustine | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Amycin 3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Semustine | Gelatin | 20%, 40%, 80%, 70% or 99.99% |
Amycin 4 | Gelatin | 20%, 40%, 80%, 70% or 99.99% | Cisplatin | Gelatin | 20%, 60%, 80%, 50% or 99.99% |
Amycin 5 | Gelatin | 20%, 60%, 80%, 50% or 99.99% | Etoposide | Gelatin | 20%, 50%, 80%, 70% or 99.99% |
Cyclophosphamide 1 | Gelatin | 20%, 50%, 80%, 70% or 99.99% | Camptothecine | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Dactinomycin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Phenesterin | Gelatin | 20%, 60%, 40%, 70% or 99.99% |
Daunorubicin 1 | Gelatin | 20%, 60%, 40%, 70% or 99.99% | Paclitaxel | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Amycin 6 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Docetaxel | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Epirubicin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Vinblastine | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Methotrexate 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Vincristine | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Fluorouracil 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Zitazonium | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Etoposide 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Piposulfan | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Flutamide 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Daunorubicin and carboplatin | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Amycin and paclitaxel | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Ciclosporin 2 | Gelatin | 20%, 40%, 80%, 70% or 99.99% |
Ciclosporin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Gelatin | 20%, 60%, 80%, 50% or 99.99% |
Levofloxacin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 3 | Gelatin | 20%, 50%, 80%, 70% or 99.99% |
Ofloxacin 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Levofloxacin 3 | Gelatin | 20%, 60%, 40%, 70% or 99.99% |
Levofloxacin 2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 4 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 1 | Gelatin | 20%, 60%, 78%, 70% or 99.99% | Levofloxacin 4 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Ofloxacin 3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Ofloxacin 5 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
Epinastine hydrochloride 2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Epinastine hydrochloride 4 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation need can be used to the disease of long-term treatment, especially needs the blood vessel embolism microsphere of the disease such as the tumor of topical therapeutic.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release.
Embodiment 24: be loaded with the preparation of biopharmaceutical macromolecular drug solution gelatine microsphere
Step (1) is identical with embodiment two.
(2) according to the biomacromolecule polysaccharide or form to such an extent that dichloromethane, acetonitrile or the ethyl acetate solution of drug solution and gelatin of complex is to form even that suspension be Water-In-Oil (W/O in equal proportion stirring in 1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 9,1: 10, whirlpool or ultrasonic 1-5 minute with metal ion
1) emulsion;
Step (3), (4), (5) are identical with embodiment one.
The microsphere that present embodiment obtains, it specifically forms proportioning such as following table:
Drug solution | Gelatin | Drug solution accounts for the percentage by weight of microsphere | Drug solution | Gelatin | Drug solution accounts for the percentage by weight of microsphere |
EPO1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | NGF | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
G-CSF1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | BDGF3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | BMP2 | Gelatin | 20%, 40%, 80%, 70% or 99.99% |
Vaccine 1 | Gelatin | 20%, 40%, 80%, 70% or 99.99% | TPA2 | Gelatin | 20%, 60%, 80%, 50% or 99.99% |
GH1 | Gelatin | 20%, 60%, 80%, 50% or 99.99% | antibody | Gelatin | 20%, 50%, 80%, 70% or 99.99% |
Insulin | Gelatin | 20%, 50%, 80%, 70% or 99.99% | Blood coagulation factor VIII | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
EGF1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | The IX genetic factor | Gelatin | 20%, 60%, 40%, 70% or 99.99% |
FGF1 | Gelatin | 20%, 60%, 40%, 70% or 99.99% | anti-RNA | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
TGF-β | Gelatin | 20%, 60%, 80%, 70% or 99.99% | RNAi | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
IGF | Gelatin | 20%, 60%, 80%, 70% or 99.99% | SiRNA | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
VEGF | Gelatin | 20%, 60%, 80%, 70% or 99.99% | DNA | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
PDGF1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | BDGF and BMP (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
ECGF | Gelatin | 20%, 60%, 80%, 70% or 99.99% | PDGF and BMP (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | TGF-β, PDGF and BMP (1: 1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | SiRNA and DNA (1: 1) | Gelatin | 20%, 40%, 80%, 70% or 99.99% |
EGF and FGF (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | BDGF and VEGF (1: 1) | Gelatin | 20%, 60%, 80%, 50% or 99.99% |
GM-CSF and G-CSF (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | IGF and GH (1: 1) | Gelatin | 20%, 50%, 80%, 70% or 99.99% |
VEGF and DNA (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | EPO2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
NGF and BMP (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | G-CSF2 | Gelatin | 20%, 60%, 40%, 70% or 99.99% |
EGF and FGF (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | GM-CSF2 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
GM-CSF and G-CSF (1: 1) | Gelatin | 20%, 60%, 80%, 70% or 99.99% | Vaccine | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
BDGF2 | Gelatin | 20%, 60%, 78%, 70% or 99.99% | EPO3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
BMP1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | G-CSF3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
TPA1 | Gelatin | 20%, 60%, 80%, 70% or 99.99% | GM-CSF3 | Gelatin | 20%, 60%, 80%, 70% or 99.99% |
The microsphere of this method preparation can be used for the disease of the frequent drug administration by injection of needs, long-term treatment, especially needs the treatment of major diseases such as anemia that disease such as the tumor of topical therapeutic, the various cause of disease cause, dwarf.High minimum can the reaching more than 70% of the microsphere envelop rate of this method preparation dashed forward and released little and almost not incomplete release, can reach zero level and discharge.
Claims (5)
1. oil-in-water-oil bag oil-Water-In-Oil prepares the method for microsphere, it is characterized in that, may further comprise the steps:
1. prepare drug solution, directly be dissolved in the water medicine or medicine be dissolved in the water through adding adjuvant;
2. the organic solution that drug solution is joined slow release or controlled-release material is to stir in the oil phase-1 or whirlpool makes it homodisperse and forms uniform suspension;
3. suspension being added in another organic solution is oil phase-2, insoluble slow release of this oil phase or controlled-release material but can extract organic solvent 2., and stirring, whirlpool or ultrasonic formation contain the emulsion of 20-500 μ m microsphere;
4. the completing steps emulsion that contains microsphere 3. being transferred to salt water W solidifies;
5. completing steps sample lyophilizing is 4. got microsphere, in this microsphere: medicine is that 0.01-50%, slow release or the controlled-release material of the weight of whole microsphere is that 20-99.99%, the adjuvant of the weight of whole microsphere is the 0-30% of the weight of whole microsphere;
Described medicine comprises small-molecule drug and macromolecular drug, and macromolecular drug is meant biopharmaceutical macromolecular drug;
Said small-molecule drug is chemotherapy of tumors class medicine or antibiotics;
Said chemotherapy of tumors class medicine is one or more mixing in AC, dactinomycin, bleomycin, daunorubicin, epirubicin, mitomycin, methylamine dish purine, fluorouracil, carboplatin, carmustine, semustine, cisplatin, etoposide, camptothecine, phenesterin, paclitaxel, Docetaxel, vinblastine, vincristine, zitazonium, etoposide, piposulfan, cyclophosphamide or the flutamide;
Said antibiotics is that ciclosporin, levofloxacin, ofloxacin or hydrochloric acid are according to one or more mixing in this spit of fland of an acid;
Described biopharmaceutical macromolecular drug is meant protein macromolecule medicine, vaccine, nucleic acid or liposome medicament, wherein:
Described protein macromolecule medicine is: erythropoietin; Recombinant human granulocyte colony stimulating factor; Granulocyte-macrophage colony stimutaing factor; Vaccine; Interferon; Growth hormone; Insulin; Epidermal growth factor; Fibroblast growth factor; Transforming growth factor; Insulin like growth factor; Vascular endothelial cell growth factor; PDGF; ECGF; Nerve growth factor; BDGF; BMP; Tissue polypeptide antigen; Antibody; Blood coagulation factor VIII or plasma thromboplastin component genetic factor; Antibody;
Described nucleic acid is: GEM 132, microRNA or gene;
The material of described slow release or controlled release is: polylactic acid; Polylactic acid-polyglycolic acid; Politef; Polrvinyl chloride; Polyethylene; Polypropylene; Polystyrene; PETG; Merlon; Hyaluronic acid; Gelatin; Collagen protein; Gather Acetic acid, hydroxy-, bimol. cyclic ester; Polybutylcyanoacrylate; Poly phosphazene; Poly phosphate; Fibrinogen; Fibrin; Polyethylene glycol-lactic acid; The polyethylene glycol-hydroxyacetic acid; Polyglycolic acid-polyethylene glycol-hydroxyacetic acid; Polylactic acid-polyglycol-polylactic acid; Or a kind of in the polycaprolactone;
The organic solution of the material of described slow release or controlled release; Wherein organic solution is meant a kind of or combination in dichloromethane, ethyl acetate, acetonitrile, heptane, chloroform and the acetone; In the organic solution of the material of this slow release or controlled release, the weight percent content of the material of slow release or controlled release is 0.5-80%;
Described oil phase-2 is: a kind of or their combination in any in surfactant, glycerol, ethanol, propylene glycol, the ethylene glycol solution, wherein:
Described their combination in any is: glycerol and ethanol add that the aqueous solution of surfactant, aqueous solution, glycerol and propylene glycol that ethanol adds surfactant add the aqueous solution of surfactant, aqueous solution, glycerol and the ethylene glycol that propylene glycol adds surfactant adds the aqueous solution of surfactant, the aqueous solution that ethylene glycol adds surfactant.
2. oil-in-water according to claim 1-oil bag oil-Water-In-Oil prepares the method for microsphere; It is characterized in that; Described adjuvant is meant a kind of or combination in any of little saccharide, polyhydroxy compounds, polysaccharide compound, amino-acid compound or inorganic salts material, wherein:
Said little saccharide is meant sucrose, trehalose, glucose, maltose or lactose;
Said polyhydroxy compounds is meant mannitol, sorbitol, glycerol, 1,2-propylene glycol, erythritol, Polyethylene Glycol, polyvinyl alcohol, PEO or polypyrrole alkane ketone;
Said polysaccharide compound is meant glucosan, sodium alginate, chitosan, starch, cellulose or cyclodextrin material;
Said amino-acid compound is meant lysine, arginine, glutamic acid or histidine;
Said inorganic salts material is meant zinc salt, calcium salt, mantoquita, magnesium salt or molybdenum salt.
3. oil-in-water according to claim 1-oil bag oil-Water-In-Oil prepares the method for microsphere, it is characterized in that in the described drug solution, the weight percent content of medicine is between the 0.2-50%.
4. oil-in-water according to claim 1-oil bag oil-Water-In-Oil prepares the method for microsphere; It is characterized in that; Described surfactant is: polyvinyl alcohol, Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, gather in sorbic alcohol, ethyl cellulose and the tween a kind of, wherein:
The weight concentration of polyvinyl alcohol is 0.5-10% or contains 0.5-10% sodium chloride salt solution; The weight concentration of Polyethylene Glycol is 0.5-20% or the saline solution that contains 0.5-10% sodium chloride; The polyvinylpyrrolidone weight concentration is 0.5-20% or contains 0.5-10% sodium chloride salt solution; The poloxamer weight concentration is 0.5-20% or contains 0.5-10% sodium chloride salt solution; To gather the sorbic alcohol weight concentration be 0.5-20% or contain 0.5-10% sodium chloride salt solution, and the ethyl cellulose weight concentration is 0.5-20% or contains 0.5-10% sodium chloride salt solution.
5. oil-in-water according to claim 1-oil bag oil-Water-In-Oil prepares the method for microsphere; It is characterized in that in the said oil phase-2, each substance weight percentage ratio is: glycerol 0-50%; Aqueous surfactant solution 0-30%, ethanol, propylene glycol, ethylene glycol 50-100%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910045024A CN101461785B (en) | 2009-01-08 | 2009-01-08 | Oil in water-oil in oil-water in oil method for preparing microballoons |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910045024A CN101461785B (en) | 2009-01-08 | 2009-01-08 | Oil in water-oil in oil-water in oil method for preparing microballoons |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101461785A CN101461785A (en) | 2009-06-24 |
CN101461785B true CN101461785B (en) | 2012-10-17 |
Family
ID=40802722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910045024A Expired - Fee Related CN101461785B (en) | 2009-01-08 | 2009-01-08 | Oil in water-oil in oil-water in oil method for preparing microballoons |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101461785B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101773479B (en) * | 2009-12-30 | 2012-09-05 | 上海交通大学 | Method for preparing shell-core double-layer microspheres |
EP2353588B1 (en) * | 2010-01-21 | 2015-04-15 | Agricultural Technology Research Institute | A sustained release preparation of factor IX |
CN102743337B (en) * | 2011-04-20 | 2014-04-16 | 国家纳米科学中心 | Nano-particulate medicinal composition and preparation method thereof |
CN102342919A (en) * | 2011-10-14 | 2012-02-08 | 上海交通大学 | Preparation method for 5-fluorouracil/PLGA (Polylactic-co-Glycolic Acid) medicine carrying microspheres |
CN102885785B (en) * | 2012-09-26 | 2014-01-15 | 复旦大学附属金山医院 | Adriamycin-containing nanometer medicament microspheres and preparation method thereof |
CN102885783B (en) * | 2012-09-26 | 2014-04-16 | 复旦大学附属金山医院 | Nanometer medicament microspheres |
CN102885710B (en) * | 2012-10-22 | 2014-10-22 | 西安雅芝生物科技有限公司 | Sodium alga acid/chitosan/collagen composite micro-ball with active components and preparation method of composite micro-ball |
CN103054812B (en) * | 2012-12-29 | 2014-04-16 | 中国人民解放军第四军医大学 | Growth factor controlled-release micro-sphere with thermo-sensitive switch and preparation method thereof |
CN103285375A (en) * | 2013-05-09 | 2013-09-11 | 中国药科大学 | Phycocyanin microsphere preparation and preparation method thereof |
US9815959B2 (en) * | 2014-02-27 | 2017-11-14 | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Method for manufacturing novel hollow particles |
CN104910415B (en) * | 2015-05-28 | 2018-03-20 | 苏州智微纳米科技有限公司 | A kind of microballoon additive and its application in microballoon industry |
CN105399810A (en) * | 2015-11-21 | 2016-03-16 | 青岛康原药业有限公司 | Preparation method for human epidermal growth factor and pharmaceutical composition capable of improving re-dissolubility of human epidermal growth factor |
CN107753934A (en) * | 2016-08-18 | 2018-03-06 | 温州医科大学 | Contain the preparation of SA mGM CSF or/and SA hTNF α biotin chitosan calcium alginate microsphere |
CN106730032A (en) * | 2016-11-15 | 2017-05-31 | 王翀 | A kind of printed material, the preparation method of tissue engineering bracket and tissue engineering bracket |
CN107099504A (en) * | 2017-05-31 | 2017-08-29 | 东莞市保莱生物科技有限公司 | A kind of candidate stem cell culture medium |
CN107034189A (en) * | 2017-05-31 | 2017-08-11 | 东莞市保莱生物科技有限公司 | A kind of candidate stem cell cultural method |
CN107320459B (en) * | 2017-07-21 | 2019-07-16 | 浙江理工大学 | It is a kind of to cooperate with controlled release for the preparation method of the polymer nano particle of medicine based on bilayer |
CN111184912B (en) * | 2019-10-15 | 2022-06-28 | 镇江市中西医结合医院(镇江市第二人民医院) | Genipin modified fibrin gel or microsphere and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410056A (en) * | 2002-10-29 | 2003-04-16 | 浙江大学 | Preparation method of water soluble anticancer medical microsphere |
CN1739795A (en) * | 2005-08-31 | 2006-03-01 | 上海交通大学 | Prepn process of slow release parathyroid hormone microballoon |
-
2009
- 2009-01-08 CN CN200910045024A patent/CN101461785B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410056A (en) * | 2002-10-29 | 2003-04-16 | 浙江大学 | Preparation method of water soluble anticancer medical microsphere |
CN1739795A (en) * | 2005-08-31 | 2006-03-01 | 上海交通大学 | Prepn process of slow release parathyroid hormone microballoon |
Non-Patent Citations (2)
Title |
---|
Patrick B.O"Donnell et al..Influence of processing on the stability and release properties of biodegradable microspheres containing thioridazine hydrochloride.《European Journal of Pharmaceutics and Biopharmaceutics》.1998,第45卷第83-94页. * |
张海龙等.多肽、蛋白质药物缓释微球研究进展.《现代食品与药品杂志》.2007,第17卷(第1期),第26-29页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101461785A (en) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101461785B (en) | Oil in water-oil in oil-water in oil method for preparing microballoons | |
CN101461786A (en) | PLA/PLGA shell-core microballoons prepared by oil in water-solid in oil method, and preparation method thereof | |
Lee et al. | Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal | |
CN101721377B (en) | Method for preparing microspheres with hydrophilic oil in ethanol, oil in hydrophilic oil, solid in oil | |
CN102885783B (en) | Nanometer medicament microspheres | |
CN101474160A (en) | Oil in oil-oil in oil-water in oil method for preparing microballoons | |
JP2014533740A (en) | Hydrophobic drug delivery material, method for producing the same, and method for delivering a drug delivery composition | |
CN102885784B (en) | Method for preparing microspheres by using oil-in-nanoparticle mixed suspension-nanometer medicament-in-oil | |
JP2003534268A (en) | Method for preparing microparticles with selected polymer molecular weight | |
CN102552215B (en) | Microcapsule lyophilized powder and preparation method thereof | |
CN108472247B (en) | Sustained release cyclosporin-loaded microparticles | |
Zhuang et al. | Preparation of particulate polymeric therapeutics for medical applications | |
CN102895197B (en) | Method for preparing microspheres through oil in nano-particle suspension-oil in oil and sustained-release microspheres | |
CN101485627A (en) | Microsphere prepared from glycerol modified solid-in-oil-in-water and preparation method thereof | |
CN107157953A (en) | A kind of psoralen polymer nanoparticle preparation and preparation method | |
CN103585113B (en) | Apigenin polylactic acid sustained release microsphere and preparation method thereof | |
CN102895192B (en) | Method for producing microsphere through oil-in-nanoparticle suspension-water-in-oil mode | |
CN106983719A (en) | A kind of docetaxel polymer nano micelle injection, its preparation method and its application in tumor is prepared | |
CN102895193B (en) | Method for preparing microspheres through oil in nano-particle suspension-oil in oil-water in oil | |
CN102188391B (en) | Method for preparing granulocyte-macrophage colony stimulating factor microsphere | |
CN102895191B (en) | Method for preparing microspheres in oil-in-nanosuspension and solid-in-oil mode | |
CN103536533B (en) | A kind of water-soluble drug liposome preparation method | |
Saini et al. | Novel drug delivery system microsphere: a review | |
CN101773479B (en) | Method for preparing shell-core double-layer microspheres | |
CN105997945A (en) | Preparation method of macromolecule nanoparticles capable of transmitting two or more types of medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121017 Termination date: 20150108 |
|
EXPY | Termination of patent right or utility model |